BS-181 is a potent and selective CDK7 inhibitor ( IC 50 =21 nM) than Seliciclib ( HY-30237 ). BS-181 is also against CDK2 , CDK5 and CDK9 with IC 50 values of 880, 3000 and 4200 nM, respectively (fails to block CDK1 , 4 and 6). BS-181 inhibits a panel of cancer cells growth (IC 50 =11.5 μM-37.3 μM) and induces cell apoptosis . BS-181 has the potential for the research of cancer therapy.
Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Apoptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.